Ebenbuild
Ebenbuild is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Ebenbuild.
Ebenbuild is a company.
Key people at Ebenbuild.
Key people at Ebenbuild.
Ebenbuild is a Munich-based healthtech startup founded in 2019 that develops digital twin technology for lungs, creating patient-specific simulation models using physics, AI, and data science to improve treatment of respiratory diseases like acute respiratory distress syndrome (ARDS).[1][2][3] The platform serves healthcare providers (e.g., ICU clinicians for personalized mechanical ventilation recommendations) and life sciences companies (e.g., optimizing inhaled drug delivery and in silico trials), addressing high mortality rates in severe lung conditions by enabling precise, individualized decision-making.[1][2][3][4] With €2.5M raised in a 2022 seed round led by High-Tech Gründerfonds and Bayern Kapital, plus a €2.3M European Innovation Council grant in 2023 and public funding via the UBIC consortium, Ebenbuild shows steady growth momentum toward scaling clinical and industrial applications.[2][5][6]
Ebenbuild emerged in Munich, Germany, in 2019 amid rising needs for personalized medicine in critical care, particularly for ARDS patients facing ~40% mortality from imprecise mechanical ventilation settings based on generic parameters like body weight.[1][2][5] Led by CEO Kei Müller, the team leveraged expertise in computational modeling to build lung digital twins from patient data like CT scans and AI, starting with ICU applications and expanding to drug development.[1][2][3] Early traction included a 2022 seed round of €2.5M from High-Tech Gründerfonds, Bayern Kapital, and business angels, followed by the 2023 EIC grant and UBIC project collaboration with top German university hospitals (e.g., Schleswig-Holstein, Augsburg, Dresden, RWTH Aachen).[2][4][5][6] These milestones validated the technology's potential to de-risk therapies and enhance translatability from preclinical to human applications.[1]
Ebenbuild rides the digital twin and AI-driven personalized medicine wave in healthtech, targeting respiratory diseases amid post-COVID emphasis on ARDS and inhaled therapies.[1][3][6] Timing aligns with regulatory shifts favoring in silico trials (e.g., FDA/EMA pilots) to cut costs and speed, plus Europe's push for AI-health integration via grants like EIC and UBIC.[2][4][5][6] Market tailwinds include a booming €50B+ digital health sector, aging populations driving lung disease prevalence, and pharma's need for precise lung delivery models amid 70%+ inhaled drug failure rates in early stages.[1][3] By enabling better outcomes and R&D efficiency, Ebenbuild influences the ecosystem, fostering adoption of computational physiology in ICUs and accelerating therapies for 500K+ annual ARDS cases globally.[2][5]
Ebenbuild is poised to expand its lung twin platform beyond ARDS into broader respiratory diseases and multi-organ models, leveraging UBIC results and EIC funds for clinical validation and commercial pilots.[4][6] Trends like AI regulatory approvals, virtual trials, and precision oncology will propel growth, potentially capturing share in the $10B+ digital twin health market. Its influence may evolve from niche innovator to ecosystem enabler, powering pharma pipelines and hospital protocols—ultimately turning digital twins from simulation tools into standard care for severe illness, maximizing patient benefit as promised.[3]
